Seroprevalence of major blood-borne infections among blood donors at Felege Hiwot referral hospital, northwest Ethiopia

Azene Dessie¹, Bayeh Abera², Fisseha Wale²

Abstract
A cross-sectional study was conducted to determine the seroprevalence of major transfusion-transmissible infections among blood donors at Felege Hiwot referral hospital, northwest Ethiopia. The overall seroprevalence of major blood-borne pathogens among blood donors was 43.2%, of which HBsAg, anti-HCV IgG, HIV seropositivity and syphilis accounted for 25%, 13.3%, 11.7% and 1.2% respectively. Crude seroprevalence of major blood born pathogens was significantly higher in commercial blood donors (56.6%) compared to voluntary (17.6%) and replacement blood donors (53.6%) (p=0.0001). [Ethiop.J.Health Dev. 2007;21(1):68-69]

Introduction
Although blood transfusion is one of the known therapeutic interventions that cut across a number of clinical disciplines, the practice is not without risks. In Africa, about 10-15 % of HIV transmission had been related to blood transfusions (1). The highest risk groups are children suffering from malaria and anaemia; women with pregnancy-related haemorrhage and victims of major trauma.

Felege Hiwot Referral Hospital is a 245 bed hospital located in Bahir Dar city, northwest Ethiopia. Being situated in a malaria dominant area, blood transfusion is one of the routine services in this hospital. However, most of the donated blood is screened for HIV alone. The national HIV prevalence among blood donors is 4.7 % (6). However, there is paucity of information about the true burden of major transfusion-transmissible infections in the study area. The purpose of this study is, therefore, to determine the seroprevalence of common blood-borne infections among the donor population.

Methods
A cross-sectional study was conducted at Felege Hiwot Referral Hospital and Bahir Dar Regional Health Research Laboratory from February 2006 to May 2006. Exclusion criteria for blood donation were current history of medication, recent history of operation, serious illness, previous blood transfusion, weight < 50kg, pregnant and lactating women, age <18 and > 60 years and blood donation for 3 months prior to the current study. Applying these criteria, 324 apparently healthy blood donors who donated blood were included in the study. At the time of blood collection, socio-demographic variables of the study population were collected using a structured questionnaire. In this study, commercial donor is a donor who gives blood for money or other form of payment and a replacement donor is a donor who gives blood when it is required by a member of the patient’s family.

Serological assays for HIV infection, Hepatitis B virus, Hepatitis C virus and Syphilis were screened by using 4th generation ELISA, Vironostika HIV Uni-Form II AG/Ab (Bio-Merieux, Boxtel, Netherlands), an immunoassay ELISA Hepanostika HBSAg UNi-Form II (Bio-Merieux, Boxtel, Netherlands), using the Human anti-HCV 3rd generation ELISA (Human Gasellschaft for Bio-chemical and diagnostic MbH, Germany) and using Rapid Plasma Reaginic (BHAT-BIO-TECH, Banglor, India) respectively. Pearson Chi-Square and 95% confidence interval were employed for group comparison of blood donors and association of variables.

Results
A total of 324 blood donors including 283 males and 41 females donated blood during the study period, out of which 152 (46.9%), 138 (42.6%) and 34 (10.5%) were commercial, replacement and voluntary donors respectively. The overall seroprevalence of major blood born pathogens (HIV, HBV, HCV and syphilis) among blood donors was 43.2%. Seroprevalence of hepatitis B virus was the highest (25%) followed by hepatitis C virus (13.3%), human immunodeficiency virus (11.7%) and syphilis (1.2%) (Table: 1). The crude seroprevalence of major blood born pathogens was significantly higher in commercial (56.6%) blood donors compared to voluntary (17.6%) and replacement blood donors (53.6%) at p=0.001).

Among multiple infected blood donors, HIV seropositive blood donors (31.6%) were found to be significantly co-infected with HBV, HCV and syphilis compared with HIV seronegative blood donors (4.9%) at P=0.0001. Among the co-infections HBV and HCV infections were found to be significantly co-existing in our study population (p<0.05).
Table 1: Seroprevalence of transfusion-transmissible infections among blood donors at Felege Hiwot Referral Hospital, Feb. 1-May 30, 2006

<table>
<thead>
<tr>
<th>Transfusion transmissible Infections (TTIs)</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV</td>
<td>81</td>
<td>25</td>
</tr>
<tr>
<td>HCV</td>
<td>43</td>
<td>13.3</td>
</tr>
<tr>
<td>HIV</td>
<td>38</td>
<td>11.7</td>
</tr>
<tr>
<td>Syphilis</td>
<td>4</td>
<td>1.2</td>
</tr>
<tr>
<td>None of the screened TTIs</td>
<td>184</td>
<td>56.8</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>324</strong></td>
<td><strong>100.00</strong></td>
</tr>
</tbody>
</table>

Discussion

This study demonstrated that the seroprevalence of blood-borne infections in the donor population is unacceptably high (43.2%). This finding is by and large higher than similar reports from other developing settings. Occurrence of at least one pathogen among blood donors was reported to be 15.9% and 26.2% from studies in Tanzania and Cameroon respectively (2, 3). Hence, even when compared with other resource-constrained settings, the burden of transfusion-transmissible infections is quite high in our study population.

As with a case of previous report from South Africa (4), the prevalence of HIV infection in the blood donor population was found to be high (11.7%). Nearly a decade ago, Rahlenbeck SI et al (7) reported a 16.7% prevalence of HIV infection among Ethiopian blood donors. Another local research work from Gondar showed crude seroprevalence of HIV was 10.6% in men and 11.9% in women among a similar study population which is in parallel with our finding (8).

Consistent with the findings of this study, the prevalence of HBV infection was reported to be higher than that of HCV infection in another East African study (5). We found that 8% of the overall blood donors and 18.6% of the infected persons had co-infections. One of the other important findings we observed in this study was the statistically significant occurrence of dual blood-borne infections among seropositive donors with HIV infection than the scenario in HIV seronegative ones. Such a higher prevalence of co-infections among HIV infected persons is likely to have a clear implication in the routine clinical care of HIV infected patients.

In agreement with the findings of this study, other research work also demonstrated high infection burden among commercial blood donors while voluntary donors were found to be comparatively safe (2). In this research work, more than half (56.6%) of the blood donors were commercial, which is one of the clear explanations for the unacceptably high prevalence of transfusion-transmissible infections. In conclusion, blood safety is an issue of major concern at Felege Hiwot Referral Hospital. Hence, blood donations should be routinely screened for HIV, HBV, HCV and syphilis using standard methods. A strict selection criterion of donors, with emphasis on getting voluntary donors is also highly recommended.

Acknowledgment

We are grateful to the Amhara Region HIV/AIDS prevention and control office for financing the research work. We also thank Bahir Dar Regional Health Research Laboratory for supply of the materials during the study.

References